Evidence mapPaperPMID 42333434Full record

ReviewChemical record (New York, N.Y.)2026

Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges.

Chiara Ragusa, Valentina Oliveri

Abstract readReview
In one paragraph

Review in Chemical record (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chiara RagusaDipartimento di Scienze Chimiche, Università degli Studi di Catania, Catania, Italy.ORCID 0009-0003-6822-481X
Valentina OliveriDipartimento di Scienze Chimiche, Università degli Studi di Catania, Catania, Italy.ORCID 0000-0001-7603-4790

Funding

ERMES 101185661Università di Catania
6 · The paper itself

Abstract

Cancer continues to be the primary cause of death despite significant progress in medicine, and finding effective therapies remains a challenge. New treatments are needed to minimize the harmful effects on the body and increase the selectivity of drugs. These therapies must also overcome cancer cell resistance and prevent metastasis. Metal-based drugs are becoming increasingly crucial for treating tumors, and copper ion-based systems and nanoparticles have been identified as having unique properties and anticancer potential. Given the key role exerted by Cu in the etiology, severity, and progression of cancer diseases, it could be a vulnerable point to target for hindering cancer development. After thoroughly analyzing what is known about the mechanism of cancer cell death through a Cu-dependent mechanism, known as cuproptosis, and its potential links with ferroptosis, we report some systems that, when coadministered with copper ions, can trigger this type of cell death. This study investigates the effectiveness of cuproptosis inducers against various types of cancers. Are these cuproptosis inducers effective in combating cancer? What limitations or disadvantages might be associated with their use? This article aims to answer these questions based on the current knowledge in this evolving area of cancer research.

Indexed as

Antineoplastic AgentsCopperCuproptosisNeoplasmsAnimalsFerroptosisHumansAntineoplastic AgentsCoppercancercancer resistancecancer therapycause of deathcopper‐based nanomaterialscopper ionophorescuproptosisprogrammed cell death

Identifiers

PMID42333434
PMCPMC13387993

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.